BiologicalDrug
Laronidase clinical trials
Also written Aldurazyme.
- studies test it
- 17
- open now
- 1
- in phase 3
- 3
- first study started
- 2001
Keep track of what changes. Save the laronidase studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 2 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 3
- Phase 3
- 3
- Phase 4
- 4
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 8
Genzyme, a Sanofi Company (8) · Masonic Cancer Center, University of Minnesota (3) · Patricia I. Dickson, M.D. (3) · Cinnagen (1) · University of California, San Francisco (1) · agnes chen (1)
Studies
Open first, then newest update. How each study uses laronidase is read from its arms, and is right about nine times in ten.
Testing it · 17
- PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)RecruitingPhase 1University of California, San FranciscoNCT04532047Written as Aldurazyme (laronidase)
- China Post-marketing Surveillance (PMS) Study of Aldurazyme®CompletedPhase 4Genzyme, a Sanofi CompanyNCT05134571Written as Laronidase
- Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I PatientsCompletedPhase 3CinnagenNCT06406153Written as Laronidase
- A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed InfantsTerminatedPhase 4Genzyme, a Sanofi CompanyNCT00418821Written as Laronidase
- Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS ITerminatedNot applicableagnes chenNCT02232477Written as Intrathecal recombinant human alpha iduronidase
- Administration of IV Laronidase Post Bone Marrow Transplant in HurlerCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT01173016Written as Laronidase
- Stem Cell Transplant w/Laronidase for HurlerCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT00176891Written as Laronidase ERT
- Intrathecal Enzyme Replacement for Hurler SyndromeCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT00638547Written as IRT Laronidase
- A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS ICompletedNot applicablePatricia I. Dickson, M.D.NCT00852358Written as laronidase
- A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years OldCompletedPhase 2Genzyme, a Sanofi CompanyNCT00146757Written as Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) DiseaseCompletedPhase 4Genzyme, a Sanofi CompanyNCT00144781Written as Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) PatientsCompletedPhase 3Genzyme, a Sanofi CompanyNCT00146770Written as Aldurazyme
- Immune Tolerance Study With Aldurazyme® (Laronidase)CompletedPhase 1/2Genzyme, a Sanofi CompanyNCT00741338Written as Laronidase
- A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated PatientsCompletedPhase 4Genzyme, a Sanofi CompanyNCT00144768Written as laronidase
- Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) DiseaseCompletedPhase 3Genzyme, a Sanofi CompanyNCT00258011Written as Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) ITerminatedPhase 1Patricia I. Dickson, M.D.NCT00215527Written as laronidase
- Extension Study of Intrathecal Enzyme Replacement Therapy for MPS ITerminatedPhase 1Patricia I. Dickson, M.D.NCT00786968Written as laronidase
Codes
What other systems call laronidase · ClinicalTrials.gg INT002214
- MeSH (NLM) C000732080laronidaseOne source NLM
- UNII (FDA) WP58SVM6R4LARONIDASEConfirmed FDA, NLM, Wikidata
- RxNorm 392509Confirmed FDA, Wikidata
- Wikidata Q20801774laronidaseConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83864LaronidaseOne source FDA
- DrugBank DB00090One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732080 | laronidase | One source NLM |
| UNII (FDA) | WP58SVM6R4 | LARONIDASE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 392509 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20801774 | laronidase | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83864 | Laronidase | One source FDA |
| DrugBank | DB00090 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.